(PharmaNewsWire.Com, May 25, 2021 ) The global creatinine assay kits market is valued at USD 182.7 Million in 2016 and is projected to reach USD 245.4 Million by 2022, at a CAGR of 5.3%. The growth of this market is mainly driven by the increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, growing awareness and adoption of preventive healthcare, favourable government initiatives to promote renal health, rapid growth in the geriatric population, and advancements in biomedical research pertaining to kidney disorders and availability of funding.
The Jaffe’s kinetic test kits segment dominated the market in 2017
The creatinine assay kits market, by type, is segmented into Jaffe’s kinetic test kits, creatinine-PAP test kits, and ELISA test kits. In 2017, Jaffe’s kinetic test kits accounted for the largest share of the market. Jaffe’s kinetic test is the oldest and most conventional method for creatinine measurement. Additionally, the wide product availability, as well as the cost-effectiveness of these kits, are some of the major factors responsible for the large share of this segment.
Based on type of sample, the blood/serum segment is expected to register the highest CAGR during the forecast period
Based on type of sample, the creatinine assay kits market is segmented into blood/serum, urine, and other samples. Other samples mainly include saliva, cerebrospinal fluid, tissue homogenate, and sweat. The blood/serum segment is expected to witness the highest CAGR over the forecast period. Most newly developed creatinine measurement kits are based on the analysis of creatinine in blood samples owing to its accuracy in inferring creatinine concentration. These are the major factors responsible for the increasing adoption of this sample type.
In 2017, North America dominated the creatinine assay kits market
In 2017, North America dominated the market followed by Europe. The large share of North America is attributed to factors such as increasing incidence of renal disorders, rising prevalence of other chronic disorders like hypertension and diabetes (which can lead to renal dysfunction), and the implementation of favorable government initiatives to increase awareness of and encourage research pertaining to kidney diseases.
The creatinine assay kits market is highly fragmented with the presence of several large as well as emerging players. Prominent players in this market include Thermo Fisher Scientific (US), Merck (Germany), Abbott Laboratories (US), Abcam (UK), Quidel (US), Enzo Life Sciences (US), Cayman Chemical (US), Crystal Chem (US), Cell Biolabs (US), Genway Biotech (US), BioAssay Systems (US), Wako Pure Chemical Industries (Japan), Tulip Diagnostics (India), BioVision (US), and Arbor Assays (US).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
